Lipocine updates LPCN 2401 development overview

Lipocine Inc. reported that it has updated the corporate presentation it uses with investors, analysts and other audiences.

Rhea-AI Filing Summary

Lipocine Inc. reported that it has updated the corporate presentation it uses with investors, analysts and other audiences. The update reflects the current status of LPCN 2401, a program being developed as an adjunct to GLP-1 therapy.

The company has received IND clearance to proceed with a proof-of-concept study of LPCN 2401, but is first seeking regulatory clarity on the development path, including study endpoints such as functional loss, before moving forward with the study. The revised investor presentation has been filed as Exhibit 99.1 to this report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine (LPCN) disclose in this 8-K filing?

Lipocine disclosed that it has updated its corporate presentation used with investors and others, and filed the revised presentation as Exhibit 99.1.

What is the current status of Lipocine’s LPCN 2401 program?

LPCN 2401 has received IND clearance for a proof-of-concept study as an adjunct to GLP-1 therapy, but Lipocine is seeking regulatory clarity on the development path before proceeding.

Why is Lipocine seeking regulatory clarity before the LPCN 2401 POC study?

Lipocine is seeking regulatory clarity regarding the development path for LPCN 2401, particularly around study endpoints such as functional loss, before starting the proof-of-concept study.

How does LPCN 2401 relate to GLP-1 therapy?

LPCN 2401 is being developed as an adjunct to GLP-1 therapy, meaning it is intended to be used alongside GLP-1 treatments rather than as a standalone replacement.

Where can investors find Lipocine’s updated corporate presentation?

The updated corporate presentation is included as Exhibit 99.1 to this report, along with an Inline XBRL cover page data file listed as Exhibit 104.

Does this Lipocine 8-K involve any major transactions or financings?

The disclosure focuses on an updated corporate presentation and the development status of LPCN 2401, rather than on major transactions or financings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/26/2025 - 09:31 AM Learn about SEC filing dates

false 0001535955 0001535955 2025-09-26 2025-09-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

September 26, 2025

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware		99-0370688
(State or other jurisdiction of incorporation)		(IRS Employer Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. Although the Company has received IND clearance to proceed with the POC study of LPCN 2401 as an adjunct to GLP-1 therapy, the Company is seeking regulatory clarity regarding the development path for LPCN 2401, in particular study endpoints such as functional loss, before proceeding with the POC study. The corporate presentation has been updated accordingly. The presentation is filed as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description
99.1		Corporate Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			LIPOCINE INC.
Date:	September 26, 2025		By:	/s/ Mahesh V. Patel
				Mahesh V. Patel
				President and Chief Executive Officer